Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0POFNN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HLCX-SS-dasatinib ADC
|
|||||
| Synonyms |
CD184 Dasatinib ADC; ADC-W-520; CD184-Dasatinib-ADC
Click to Show/Hide
|
|||||
| Organization |
Ambrx, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
.
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
3
|
|||||
| Structure |
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
C-X-C chemokine receptor type 4 (CXCR4)
|
Antigen Info | ||||
| Payload Name |
Dasatinib
|
Payload Info | ||||
| Therapeutic Target |
Breakpoint cluster region protein (BCR)
|
Target Info | ||||
| Linker Name |
Dasatinib disulfide cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Nonspecific conjugation of the lysyl amino groups of the antibody with S-4FB linker (Solulink).
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.